Chinese maker and OEM/ODM supplier of eyeglass lenses, frames and sunglasses for global eyewear brands and retailers.
Chinese maker and OEM/ODM supplier of eyeglass lenses, frames and sunglasses for global eyewear brands and retailers.
In one line: China's answer to an eyewear ODM supplier.
Moat: narrow (scale, cost advantage, customer qualification). Large-scale optical manufacturing capacity and qualified OEM relationships with global eyewear brands.
Headquarters: Shanghai/Danyang, China · Employees: 2,890
Size Shanghai Conant Optical (2276.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $2.25B, the 386th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$35.86 on 18 Nov 2026.
Performance Over six months the shares fell 16.8%, against +1.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue grew 8.4% over the last twelve months (peer median +6.3%); the operating margin is 29.3% (peer median 14.9%).
Valuation It trades at 22.1× forward earnings against a peer median of 24.0× (8th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +14%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.5 points above its cost of capital (5.6% WACC).
Next results Next results expected around 6 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$2.54B | HK$2.37B | HK$2.23B | HK$1.94B | HK$1.82B |
| Revenue growth | — | +6% | +15% | +7% | — |
| Gross profit | HK$1.09B | HK$995M | HK$883M | HK$750M | HK$625M |
| EBITDA | HK$877M | HK$747M | HK$592M | HK$492M | HK$410M |
| Net income | HK$655M | HK$605M | HK$464M | HK$361M | HK$289M |
| Free cash flow | HK$28.0M | HK$266M | HK$274M | HK$385M | HK$76.3M |
| Capital expenditure | HK$422M | HK$320M | HK$244M | HK$146M | HK$139M |
| Total debt | n/a | HK$333M | HK$338M | HK$237M | HK$399M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Conant Optical 2276.HK | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% |
| EssilorLuxottica EL.PA | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% |
| Hoya 7741.T | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% |
| Mingyue Optical Lens 301101.SZ | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2276.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.2% | -0.8% | 10th lowest of 21 |
| 6-month return | -16.8% | +1.1% | 6th lowest of 20 |
| Distance from 52-week high | -46.1% | -20.1% | 5th lowest of 21 |
| Revenue growth (TTM) | +8.4% | +6.3% | 9th highest of 20 |
| Operating margin | 29.3% | 14.9% | 2nd highest of 20 |
| Forward P/E | 22.1× | 24.0× | 8th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -1.1% | 10.7% | 4th least demanding of 14 |
| Growth delivered (Del g) | +14.1% | +10.2% | 5th highest of 14 |
| Hurdle (Req g minus delivered) | -15.2 pp | -2.2 pp | 3rd least demanding of 14 |
| ROIC minus cost of capital | +18.5 pp | +1.8 pp | 4th highest of 20 |
| EV / EBITDA | 18.1× | 15.7× | 6th most expensive of 14 |
| Net debt / EBITDA | -2.1× | 1.2× | 2nd least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Medacta MOVE.SW | Switzerland | $2.48B | -28% | +8% | 15% | 24.0× | n/a | n/a |
| EBOS EBO.AX | Australia | $2.50B | +7% | +3% | 3% | 15.7× | 4.7% | +6.8% |
| Ottobock SE & Co. KGaA OBCK.DE | Germany | $2.65B | -30% | +5% | 17% | 12.3× | -1.2% | +8.0% |
| Celcuity CELC | United States | $2.73B | -60% | n/a | n/a | n/a | n/a | n/a |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |